{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T07:33:28Z","timestamp":1792740808675,"version":"4.5.0"},"reference-count":24,"publisher":"BMJ","issue":"10","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Br J Ophthalmol"],"published-print":{"date-parts":[[2019,10]]},"abstract":"<jats:sec><jats:title>Background\/aims<\/jats:title><jats:p>To evaluate the status of myelin oligodendrocyte glycoprotein antibodies (MOG-IgG) in chronic relapsing inflammatory optic neuropathy (CRION) and investigate its different clinical characteristics and prognosis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients diagnosed with CRION were recruited by the Neuro-ophthalmology Department of the Chinese People's Liberation Army General Hospital from December 2015 to April 2017. Based on antibody status, they were assigned to either the MOG-CRION or seronegative-CRION groups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 33 patients (38 eyes) were assessed and divided into the following groups: 22 (66.7%) MOG-CRION and 11 (33.3%) seronegative-CRION. The ratio of female to male was 1:1, and 81.8% of total CRION patients were adults (\u226518 years). A total of 29 eyes (76.3%) showed severe visual loss (&lt;20\/200) during the first optic neuritis episode, and 37 eyes (72.5%) demonstrated good visual recovery (&gt;20\/40) during the final follow-up. The mean onset age of MOG-CRION patients was 28 \u00b1 16 years (range 6\u201362), which was significantly younger than that of seronegative-CRION (45 \u00b1 12 years, range 22\u201359) (p=0.029). The intraorbital and canalicular segments were highly involved in the orbital MRI of CRION patients. During the final follow-up, MOG-CRION patients had more bilateral involvement (p=0.008) and higher annualised relapse rates compared with the seronegative-CRION patients (p=0.019).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>CRION was predominantly found in adults with unilateral ON and exhibited a higher rate of seropositive MOG-IgG. MOG-CRION, which may be a disparate subtype of MOG-IgG-induced demyelinating disease that needs further investigation, was found in younger patients at onset, with more bilateral involvement and more relapse tendency.<\/jats:p><\/jats:sec>","DOI":"10.1136\/bjophthalmol-2018-313142","type":"journal-article","created":{"date-parts":[[2018,12,4]],"date-time":"2018-12-04T22:25:16Z","timestamp":1543962316000},"page":"1423-1428","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":42,"title":["Antibodies to myelin oligodendrocyte glycoprotein in chronic relapsing inflammatory optic neuropathy"],"prefix":"10.1136","volume":"103","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2205-968X","authenticated-orcid":false,"given":"Hongjuan","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huanfen","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junqing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quangang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shihui","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2018,12,4]]},"reference":[{"key":"2020050713022490000_103.10.1423.1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awg045"},{"key":"2020050713022490000_103.10.1423.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)17551-X"},{"key":"2020050713022490000_103.10.1423.3","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2008.146894"},{"key":"2020050713022490000_103.10.1423.4","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-013-6957-4"},{"key":"2020050713022490000_103.10.1423.5","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-016-0718-0"},{"key":"2020050713022490000_103.10.1423.6","first-page":"406","article-title":"Neuromyelitis optica spectrum disorders with Aquaporin-4 and Myelin-Oligodendrocyte Glycoprotein antibodies in Turkish population: a comparative study","volume":"24","author":"Idiman","year":"2018","journal-title":"Mult Scler J"},{"key":"2020050713022490000_103.10.1423.7","doi-asserted-by":"crossref","first-page":"e131","DOI":"10.1212\/NXI.0000000000000131","article-title":"Anti-MOG antibodies are frequently associated with steroid-sensitive recurrent optic neuritis","volume":"2","author":"Chalmoukou","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2020050713022490000_103.10.1423.8","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1301296"},{"key":"2020050713022490000_103.10.1423.9","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s11940-018-0502-9","article-title":"Pediatric neuromyelitis optica spectrum disorders","volume":"20","author":"Gombolay","year":"2018","journal-title":"Curr Treat Options Neurol"},{"key":"2020050713022490000_103.10.1423.10","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2017-316880"},{"key":"2020050713022490000_103.10.1423.11","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(13)70259-X"},{"key":"2020050713022490000_103.10.1423.12","first-page":"616","article-title":"The diagnosis and treatment of optic neuritis","volume":"112","author":"Wilhelm","year":"2015","journal-title":"Dtsch Arztebl Int"},{"key":"2020050713022490000_103.10.1423.13","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2018-312399"},{"key":"2020050713022490000_103.10.1423.14","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2017-311177"},{"key":"2020050713022490000_103.10.1423.15","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.jneuroim.2016.09.007","article-title":"Different etiologies and prognoses of optic neuritis in demyelinating diseases","volume":"299","author":"Akaishi","year":"2016","journal-title":"J Neuroimmunol"},{"key":"2020050713022490000_103.10.1423.16","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ajo.2018.07.020","article-title":"Myelin oligodendrocyte glycoprotein antibody-positive optic neuritis: clinical characteristics, radiologic clues, and outcome","volume":"195","author":"Chen","year":"2018","journal-title":"Am J Ophthalmol"},{"key":"2020050713022490000_103.10.1423.17","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.ophtha.2018.03.041","article-title":"Aquaporin-4 and myelin oligodendrocyte glycoprotein autoantibody status predict outcome of recurrent optic neuritis","volume":"125","author":"Jitprapaikulsan","year":"2018","journal-title":"Ophthalmology"},{"key":"2020050713022490000_103.10.1423.18","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1001\/jamaophthalmol.2017.6757","article-title":"Prevalence of myelin oligodendrocyte glycoprotein and aquaporin-4-IgG in patients in the optic neuritis treatment trial","volume":"136","author":"Chen","year":"2018","journal-title":"JAMA Ophthalmol"},{"key":"2020050713022490000_103.10.1423.19","doi-asserted-by":"publisher","DOI":"10.1097\/WNO.0b013e31829f39f1"},{"key":"2020050713022490000_103.10.1423.20","doi-asserted-by":"publisher","DOI":"10.4103\/0972-2327.61280"},{"key":"2020050713022490000_103.10.1423.21","doi-asserted-by":"publisher","DOI":"10.1097\/WNO.0b013e318283c3ed"},{"key":"2020050713022490000_103.10.1423.22","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s10384-018-0561-1","article-title":"Diagnosis and treatment of anti-myelin oligodendrocyte glycoprotein antibody positive optic neuritis","volume":"62","author":"Kezuka","year":"2018","journal-title":"Jpn J Ophthalmol"},{"key":"2020050713022490000_103.10.1423.23","doi-asserted-by":"publisher","DOI":"10.1186\/1742-2094-8-184"},{"key":"2020050713022490000_103.10.1423.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2015.12.004"}],"container-title":["British Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bjophthalmol-2018-313142","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,26]],"date-time":"2020-09-26T08:58:55Z","timestamp":1601110735000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjo.bmj.com\/lookup\/doi\/10.1136\/bjophthalmol-2018-313142"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,4]]},"references-count":24,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2019,9,19]]},"published-print":{"date-parts":[[2019,10]]}},"alternative-id":["10.1136\/bjophthalmol-2018-313142"],"URL":"https:\/\/doi.org\/10.1136\/bjophthalmol-2018-313142","relation":{},"ISSN":["0007-1161","1468-2079"],"issn-type":[{"value":"0007-1161","type":"print"},{"value":"1468-2079","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,4]]}}}